Physician profile
Marco A Nova
NPI 1376515510
$18,242.50
in general payments reported to CMS, 2019-2025
43 companies · $1,568 in 2025
The $1,568 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,796 · 2020: $1,198 · 2021: $3,259 · 2022: $2,533 · 2023: $1,887 · 2024: $1,001 · 2025: $1,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,342 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,341.87 |
| Education | $114.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,692.65 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $2,189.75 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,666.30 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $1,403.80 | 2019-2025 | |
| Lilly USA, LLC | $1,206.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $971.62 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $890.36 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $747.18 | 2021-2025 | |
| Horizon Therapeutics Plc | $584.18 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $523.66 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Abbott Laboratories | $309.54 | 2019-2025 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.78 | 2019-2024 | Synjardy, Jardiance |
| Amarin Pharma, INC. | $240.90 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $240.68 | 2019-2023 | Steglatro |
| Pfizer INC. | $233.59 | 2019-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Nova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.